http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-079510-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-48 |
| filingDate | 2010-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-079510-A1 |
| titleOfInvention | DERIVATIVES OF QUINOLINAMIDE POSITIVE MODULATORS OF M1 MUSCARINIC RECEPTORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THEM IN THE TREATMENT OF ALZHEIMER, SCHIZOPHRENIA AND OTHER NERVIO SYSTEMS. |
| abstract | Claim 1: A compound of the formula (1) wherein X1 is selected from the group consisting of (1) N, and (2) N 'O; X2-X3 is selected from the group consisting of (1) -CH2-CH2-, (2) -O-CH2-, (3) -CH2-O-, or (4) -CH2-; each of X4, X5, X6 and X7 is selected from the group consisting of (1) N, (2) N «O, (3) CH, (4) O, provided that one of X4, X5, X6 and X7 it may be absent, thereby forming a five-member ring; R1 selects from the group consisting of (1) hydrogen, (2) halogen, (3) -C1-6 alkyl, (4) -C2-6 alkynyl, (4) phenyl, (5) = O, (6) = CH2, (7) hydroxyl, wherein the alkyl, alkynyl or phenyl group R1 is optionally substituted with one or more (a) hydroxyl, or (b) halogen; R2A and R2B, independently-select from the group consisting of (1) hydrogen, (2) hydroxyl, and (3) halogen, or R2A and R2B together form = O; R3 is optionally present in one or more of the carbon atoms of the ring, and is selected - independently - from the group consisting of (1) halogen, (2) -O-C1-6 alkyl, (3) -S -C1-6 alkyl, or (4) a heteroaryl group, which is an aromatic cyclic group, having between five and twelve ring atoms; said ring atoms are selected from C, O, N, N 'O or S, at least one of which is O, N, N' O or S, where the heteroaryl is optionally substituted with C1-6 alkyl; R4 is optionally present in one or more of the ring atoms and is selected from the group consisting of (1) hydroxyl, (2) halogen, (3) -C 1-6 alkyl, (4) -O-C 1-6 alkyl , (5) -S-C1-6 alkyl, (6) -C3-8 cycloalkyl, (7) -C6-10 aryl, (8) -CN, (9) a heteroaryl group, which is an aromatic cyclic group, which has between five and twelve atoms in the ring; said ring atoms are selected from C, O, N, N "O or S, at least one of which is O, N, N" O or S, (10) -O-heterocyclyl, (11) -NRARB, where RA and RB are selected from the group consisting of (a) hydrogen, or (b) -C1-6 alkyl, or RA and RB are linked together with the nitrogen to which they are attached to form a 4-6 membered carbocyclic ring , where one or two of the carbon atoms of the ring is optionally replaced by a nitrogen, oxygen or sulfur, and the ring is optionally substituted with one or more (a) halogen, (b) hydroxyl, (c) C1-6 alkyl , (d) -O-C 1-6 alkyl, (e) -C (= O) - (O) n-C 1-6 alkyl; where n is 0-1; and the alkyl, cycloalkyl, aryl or heteroaryl group R 4 is optionally substituted with one or more (a) halogen, (b) hydroxy, (c) -O-C 1-6 alkyl, (d) -C 1-6 alkyl, (e ) -S-C 1-6 alkyl, or (f) a heteroaryl group, which is an aromatic cyclic group, having between five and twelve ring atoms; said ring atoms are selected from C, O, N, N 'O or S, at least one of which is O, N, N' O or S, where the alkyl, aryl or heteroaryl moiety is optionally substituted with one or plus (i) halogen, (ii) hydroxy, (iii) -O-C 1-6 alkyl, or (iv) -C 1-6 alkyl; or two R4 groups are joined together to form a fused ring heteroaryl group of three or four atoms; said ring atoms are selected from C, O, N, N 'O or S, at least one of which is O, N, N' O or S, or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2009-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.